Literature DB >> 12508152

Human T lymphocyte response to Borrelia burgdorferi infection: no correlation between human leukocyte function antigen type 1 peptide response and clinical status.

Richard S Kalish1, Jonathan A Wood, William Golde, Robert Bernard, Larry E Davis, Roger C Grimson, Patricia K Coyle, Benjamin J Luft.   

Abstract

We tested the hypothesis that cross-reactivity between the outer surface protein A (OspA) of Borellia burgdorferi and human leukocyte function antigen (LFA) type 1 mediates chronic autoimmune sequelae of Lyme disease. T cell response was studied in subjects with Lyme disease presenting with erythema migrans alone (n=36), erythema migrans with neurological disease (n=12), and chronic Lyme disease syndrome (n=20), as well as healthy control subjects from Lyme-endemic (n=50) and -nonendemic (n=18) regions. Antigens included recombinant OspA and OspC (all strain B31) and human LFA-1 peptide (IYVIEGTSKQDLTSF). Proliferation to OspA was detected in 11 (28%) of 39 of subjects presenting with erythema migrans, which increased to 50% at 4 weeks of follow-up. Reactivity to OspA and LFA-1 was significantly correlated (P<.001) and was observed in 18 (78%) of 23 of OspA-responsive subjects. However, there was no correlation between T cell response to human LFA-1 peptide and clinical status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12508152     DOI: 10.1086/346059

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.

Authors:  Göran Günther; Mats Haglund
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  The role of infections in autoimmune disease.

Authors:  A M Ercolini; S D Miller
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

3.  An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope.

Authors:  Theresa A Willett; Abbie L Meyer; Eric L Brown; Brigitte T Huber
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-23       Impact factor: 11.205

Review 4.  Lyme Disease Frontiers: Reconciling Borrelia Biology and Clinical Conundrums.

Authors:  Vladimir V Bamm; Jordan T Ko; Iain L Mainprize; Victoria P Sanderson; Melanie K B Wills
Journal:  Pathogens       Date:  2019-12-16

5.  Differential diagnoses of suspected Lyme borreliosis or post-Lyme-disease syndrome.

Authors:  M F Seidel; A Belda Domene; H Vetter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-09       Impact factor: 3.267

6.  Lyme disease: the next decade.

Authors:  Raphael B Stricker; Lorraine Johnson
Journal:  Infect Drug Resist       Date:  2011-01-07       Impact factor: 4.003

7.  Immunogenetic Markers Definition in Latvian Patients with Lyme Borreliosis and Lyme Neuroborreliosis.

Authors:  Lilija Kovalchuka; Svetlana Cvetkova; Julija Trofimova; Jelena Eglite; Sandra Gintere; Irina Lucenko; Barbara Oczko-Grzesik; Ludmila Viksna; Angelika Krumina
Journal:  Int J Environ Res Public Health       Date:  2016-12-01       Impact factor: 3.390

8.  Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.

Authors:  Heidelore Hofmann; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Andreas Krause; Sebastian Rauer; Bernhard Ruf
Journal:  Ger Med Sci       Date:  2017-09-05

9.  Guidelines for diagnosis and treatment in neurology - Lyme neuroborreliosis.

Authors:  Sebastian Rauer; Stephan Kastenbauer; Heidelore Hofmann; Volker Fingerle; Hans-Iko Huppertz; Klaus-Peter Hunfeld; Andreas Krause; Bernhard Ruf; Rick Dersch
Journal:  Ger Med Sci       Date:  2020-02-27

10.  Direct Toll-like receptor 2 mediated co-stimulation of T cells in the mouse system as a basis for chronic inflammatory joint disease.

Authors:  Vera Sobek; Nico Birkner; Ingrid Falk; Andreas Würch; Carsten J Kirschning; Hermann Wagner; Reinhard Wallich; Marinus C Lamers; Markus M Simon
Journal:  Arthritis Res Ther       Date:  2004-07-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.